Methodological and reporting quality evaluation of Buyang Huanwu decoction for experimental cerebral ischemia–reperfusion injury: a systematic review
Open Access
- 13 January 2023
- journal article
- review article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 396 (5) , 831-849
Abstract
Buyang Huanwu decoction, a classic traditional Chinese prescription, has been used to prevent and treat stroke for hundreds of years. An increasing number of the laboratory research on Buyang Huanwu decoction used in treating cerebral ischemia–reperfusion injury have been published recently. However, the problem of methodological and reporting quality of some studies is lack of assessment. This study aims to evaluate the methodological and reporting quality of the research on Buyang Huanwu decoction against experimental cerebral ischemia–reperfusion injury. A comprehensive search on six databases was performed. Two researchers independently screened the literature considering the eligibility criteria. Methodological and reporting quality of the included studies were evaluated by the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) risk-of-bias tool and Animal Research: Reporting of In Vivo Experiments (ARRIVE) guideline. Forty-five studies met the inclusion criteria. No study achieved a decent overall rating in using the SYRCLE tool (percentage of items with “low risk” ≥ 50%). Of the 22 items on the SYRCLE tool, only 7 items (31.82%) were rated as “low risk” in more than 50% of the included studies. Of the 39 items of ARRIVE guideline, 14 (35.9%) items were rated as “yes” in more than 50% of the included studies. The methodological and reporting quality of Buyang Huanwu decoction for experimental cerebral ischemia–reperfusion injury was substandard, which needed to be further improved. The limitations should be addressed when planning similar studies in the future. Additionally, these findings provided evidence-based guidance for future preclinical studies evaluating the efficacy of Buyang Huanwu decoction in the treatment of cerebral ischemia–reperfusion injury.Keywords
This publication has 37 references indexed in Scilit:
- Buyang huanwu decoction promotes angiogenesis via vascular endothelial growth factor receptor-2 activation through the PI3K/Akt pathway in a mouse model of intracerebral hemorrhageBMC Complementary and Alternative Medicine, 2015
- SYRCLE’s risk of bias tool for animal studiesBMC Medical Research Methodology, 2014
- Buyang Huanwu Decoction for Healthcare: Evidence‐Based Theoretical Interpretations of Treating Different Diseases with the Same Method and Target of VascularityEvidence-Based Complementary and Alternative Medicine, 2014
- Clinical Efficacy and Safety of Buyang Huanwu Decoction for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 19 Randomized Controlled TrialsEvidence-Based Complementary and Alternative Medicine, 2012
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal ResearchVeterinary Clinical Pathology, 2012
- Neuroprotective effect of Buyang Huanwu Decoction against focal cerebral ischemia/reperfusion injury in rats – Time window and mechanismJournal of Ethnopharmacology, 2012
- Guidelines for reporting experiments involving animals: the ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Buyang Huanwu Decoction can improve recovery of neurological function, reduce infarction volume, stimulate neural proliferation and modulate VEGF and Flk1 expressions in transient focal cerebral ischaemic rat brainsJournal of Ethnopharmacology, 2007
- Comparison of treatment effects between animal experiments and clinical trials: systematic reviewBMJ, 2006
- Translation of Research Evidence From Animals to HumansJAMA, 2006